"Moderna's Unexpected Profit and RSV Vaccine Roadmap"
TL;DR Summary
Moderna surprised with a fourth-quarter profit, attributing it to cost cutting and deferred payments, while also outlining plans for its experimental RSV vaccine. The company reported a decline in COVID-19 vaccine sales but expects a U.S. approval decision for its RSV shot by May 12. Moderna also anticipates data from late-stage trials of its next generation COVID shot and other combination vaccines this year, reaffirming its 2024 sales forecast despite a projected revenue decrease.
- Moderna reports surprise profit, sets out road map for RSV vaccine Yahoo Finance
- Moderna posts surprise quarterly profit even as Covid vaccines sales plummet CNBC
- Moderna posts surprise quarterly profit even as COVID sales continue to slide MarketWatch
- Moderna Stock Jumps on Surprise Profit, Sales Ahead of Expectations Barron's
- Moderna: Q4 Earnings Snapshot Quartz
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
3 min
vs 3 min read
Condensed
87%
591 → 74 words
Want the full story? Read the original article
Read on Yahoo Finance